已传文件：photo/1792401541.png
ISL@bCOF maintains the COF structure, with the pores filled after drug loading, and the boron-oxygen bonds enable glucose-responsive release; the microneedle array remains intact, with mechanical properties suitable for puncturing, and can stay in the skin to continuously release ISL in response to glucose. In vitro, ISL@bCOF inhibits ZBP1 expression and pro-inflammatory factors, reduces ROS, promotes M2 markers, and suppresses M1 markers; intervention or inhibition of ZBP1 can alter its immune-modulatory effects, supporting a target-dependent mechanism. In vivo, the microneedle group shows faster wound closure, improved re-epithelialization and collagen deposition, more orderly collagen fiber arrangement, increased angiogenesis and cell proliferation, reduced inflammatory infiltration, and macrophage polarization shifts toward a reparative phenotype.
We focus on custom functional materials in the field of nanomedicine. We can develop biofunctional nanomaterials tailored to your experimental needs, controlling material structure, particle size, and surface modifications, with a full set of characterization and testing. Our solutions can be repeatedly optimized, with full technical support, supporting targeted delivery, bioimaging, nano-therapeutics, and related research projects. Feel free to provide your specifications, and we will evaluate a custom plan.
Engineer Zhang 17715390137 Engineer Chen 18914047343
